Pharma BD Deal Intelligence
Every major asset from Roche's 2002 Antisoma pipeline deal failed in the clinic; Roche walked away years before the results even came in, and Antisoma itself dissolved as a drug company.
Full analysis, sources & comparables →Antisoma starts licensing spree with cancer deal, licensing virtually its entire pipeline to Roche, including lead anti-cancer antibody pemtumomab in phase…
Antisoma reports narrowed losses; future strong on Roche product deal, citing up-front cash and equity and milestone potential from the partnership.
Antisoma re-licensed AS1404 to Novartis in an $890M deal after Roche returned rights, suggesting the original Roche alliance under-monetized individual assets…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Announced November 2002. Broad strategic alliance: Antisoma licensed virtually its entire pipeline to Roche. $43M upfront cash plus equity, $6.56M for a ~10% stake; potential $500M+ in milestones plus 10-20% royalties.
Every major asset from Roche's 2002 Antisoma pipeline deal failed in the clinic; Roche walked away years before the results even came in, and Antisoma itself dissolved as a drug company.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Roche Holding AG / Antisoma plc (this deal) | 2002 | $500M | 20 |
| Roche Holding AG / Chugai Pharmaceutical Co. Ltd. | 2002 | $1.4B | 100 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| Roche Holding AG / Corange Ltd. (Boehringer Mannheim Group) | 1997 | $11.0B | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2007 | $3.4B | 88 |
| Roche Holding AG / Foundation Medicine, Inc. | 2015 | $1.1B | 87 |
| Roche Holding AG / Foundation Medicine, Inc. | 2018 | $5.3B | 85 |
← Browse all deals · How we score deals
More: 2002 deals · Roche Holding AG deals